Rockwell Medical: The Turnaround Is Looking Real
RMTI shows growth with gross margins rising to 18% in Q2 2024. Potential EBITDA growth could drive share price to $9 by 2028. CEO Mark Strobeck's arrival has stabilized RMTI after a tumultuous period. Rockwell is the largest supplier in its niche with growing market opportunities. Risks include product quality and reliance on major clients like DaVita.
View signal analysis